戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 diotherapy, which continued until the end of conformal radiotherapy.
2 ere treated with high-dose three-dimensional conformal radiotherapy.
3 f predicting outcome after three-dimensional conformal radiotherapy.
4 al than that achieved with three-dimensional conformal radiotherapy (3D CRT), allowing dose reduction
5                 A recent parallel-opposed 3D-conformal radiotherapy (3D-CRT) study in mice compared d
6 , new technologies such as three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated e
7                  Compared with 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radi
8                            Patients received conformal radiotherapy after definitive surgery (125 pat
9                                              Conformal radiotherapy allows a smaller amount of rectum
10 edulloblastoma or PNET patients treated with conformal radiotherapy and HDC are typically transient a
11 ated conformal techniques (three-dimensional conformal radiotherapy and intensity-modulated radiother
12 o define the maximally accelerated course of conformal radiotherapy and to describe the short-term an
13 t irradiation delivered by three-dimensional conformal radiotherapy are affected by treatment techniq
14 ts with NSCLC treated with three-dimensional conformal radiotherapy at Memorial Sloan-Kettering Cance
15 ment may be achieved with dose escalation in conformal radiotherapy, by the addition of cytotoxic che
16       In men with localised prostate cancer, conformal radiotherapy (CFRT) could deliver higher doses
17  animal IMRT (SA-IMRT) and three-dimensional conformal radiotherapy (CRT) in a model application, oxy
18                                 Biologically conformal radiotherapy (dose painting) based on molecula
19 ears of follow-up showed that escalated-dose conformal radiotherapy improved biochemical progression-
20 ted conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prosta
21 ng ATM inhibitors in combination with highly conformal radiotherapy or high-dose rate brachytherapy.S
22 n 28 daily fractions of 1.8 Gy) in either 3D conformal radiotherapy or intensity modulated radiothera
23 site, stage, nodal status, three-dimensional conformal radiotherapy or intensity modulated radiothera
24  (59.4 Gy in 33 fractions; three-dimensional conformal radiotherapy or intensity-modulated radiothera
25         A modest dose increase of 8 Gy using conformal radiotherapy resulted in a substantial improve
26 l and biochemical control (bNED) rates after conformal radiotherapy (RT).
27  a randomized clinical trial of stereotactic conformal radiotherapy (SCRT) compared with conventional
28 n low-grade gliomas, stereotactically guided conformal radiotherapy should lead to a significant redu
29 nt chemotherapy, hypoxic-cell modifiers, and conformal radiotherapy, so that care of patients with no
30        However, in the present era of highly conformal radiotherapy, steep dose gradients over at-ris
31 nagement of these patients, including use of conformal radiotherapy, stereotactic body radiation ther
32 ce for application of stereotactic and other conformal radiotherapy techniques in treating brain tumo
33 or proton therapy (rather than 3-dimensional conformal radiotherapy) to reduce radiation exposure to
34 ion, ethnic origin, sex, age when undergoing conformal radiotherapy, total radiotherapy dose, number
35 re randomly assigned (1:1) to receive either conformal radiotherapy (up to 50.4 Gy; 28 doses of 1.8 G
36                            Three dimensional conformal radiotherapy was mandatory, and intensity-modu
37                                  Accelerated conformal radiotherapy was well tolerated in a high-risk
38 apy is an advanced form of three-dimensional conformal radiotherapy which allows delivery of high dos
39 n therapy for 3-6 months before the start of conformal radiotherapy, which continued until the end of
40 urvival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and
41  of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radio
42 median follow-up of 10 years, escalated-dose conformal radiotherapy with neoadjuvant androgen depriva
43 atients treated with immediate postoperative conformal radiotherapy (without delay or chemotherapy),